Antipyretic TRIZ Cases

Potassium and trometamol asiatic acid salts treat pulmonary fibrosis by reducing lung tissue damage.

A menthol monolithic matrix with a gastro-resistant coating solves homogeneous distribution issues by ensuring controlled colon release.

A bispecific antibody binds FcεRI and FcγRIIB receptors to co-aggregate them on immune cells.

Anti-TLR7 antibodies bind cell surface TLR7 to resolve safety and specificity trade-offs in autoimmune treatment.

Humanized anti-sclerostin antibodies resolve immunogenicity trade-offs by modifying CDR sequences to enhance binding affinity and stability.

Combining levocetirizine and montelukast blocks histamine release and leukotriene actions to treat anaphylaxis.

An anti-TIGIT antibody blocks TIGIT ligand interactions to restore antitumor immunity against cancer cells.

Engineered antibody variants with asymmetric Fc region modifications drive selective hetero-oligomerization.

Proteolytic cleavage of the inhibitor peptide restores antigen-binding activity at disease tissues, reducing side effects from normal tissue exposure.

A personalized dosing system adjusts biologic drug levels using pharmacokinetic feedback.

Engineered anti-TNF-alpha antibodies prevent large immune complex formation through optimized dissociation kinetics.

Implantable chitin sponges extend analgesia duration while minimizing systemic side effects from frequent dosing.

Anti-TL1A antibodies reduce Th17 pathways and tissue fibrosis, addressing inadequate response variability in ulcerative colitis patients.

A multilayered neural crest stem cell sheet embeds cells in a biodegradable hydrogel scaffold to enhance physical adhesion and bioactive factor accumulation.

Specific cis-carboxylic acids block bitter receptors to eliminate metallic off-notes from artificial sweeteners.

Segmented shroud arms navigate constrained spaces to prevent accidental retraction and needle stick injuries.

Injecting a single dose of firocoxib into the sow reduces piglet pain during processing while avoiding tissue residue risks from prolonged meloxicam exposure.

A topical analgesic composition uses a composite of humectants and emollients to deliver pain relief without volatile alcohol.

Modified anti-oxMIF antibodies reduce aggregation potential through targeted amino acid substitutions in variable domains.

Cyclized thioether peptide dimers inhibit α4β7 integrin binding to MAdCAM through specific structural rigidity.

Type II anti-CD20 antibodies overcome low response rates by translocating CD20 into lipid rafts and conjugating maytansinoids for enhanced efficacy.

Optimized CDR3 regions enhance antibody specificity and affinity for CD38, resolving cross-reactivity issues in multiple myeloma treatment.

Racemic aminopterin formulation utilizes gastrointestinal selective absorption of the active L-isomer to reduce production costs and regulatory burden.

Germinating hemp seeds elevates cannflavin concentration, resolving the contradiction between natural composition and therapeutic potential.

Segmented synthesis of azaindoles via bromination, tosylation, and esterification reduces manufacturing costs for Janus kinase inhibitors.

A high-speed direct compression process uses a stirring feeder to aerate powder compositions containing crystalline cellulose.

High-concentration anti-VLA-1 formulation stabilizes antibodies to enable effective subcutaneous injection for inflammatory disorders.